A lawsuit has been filed against Teva Pharmaceuticals and 19 other major generic drug manufacturers, alleging a broad conspiracy to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade for over 100 different generic drugs.
The lawsuit, filed in U.S. District Court for the District of Connecticut, also names 15 individual senior executive defendants responsible for sales, marketing, pricing, and operations. The drugs at issue account for billions of dollars of sales in the United States, and the alleged schemes increased prices affecting the health insurance market, taxpayer-funded healthcare programs like Medicare and Medicaid, and individuals who must pay artificially-inflated prices for their prescription drugs.
Louisiana Attorney General Jeff Landry joined Connecticut Attorney General William Tong and 42 other attorneys general in the lawsuit, which alleges that the drug manufacturers engaged in a coordinated and systematic campaign to conspire with each other to fix prices, allocate markets, and rig bids for more than 100 different generic drugs.
According to the lawsuit, the drugs span all types, including tablets, capsules, suspensions, creams, gels, ointments, and classes, including statins, ace inhibitors, beta blockers, antibiotics, anti-depressants, contraceptives, non-steroidal anti-inflammatory drugs, and treat a range of diseases and conditions from basic infections to diabetes, cancer, epilepsy, multiple sclerosis, HIV, ADHD, and more. In some instances, the coordinated price increases were over 1,000 percent.
Louisiana patients have been directly impacted by the alleged conspiracy, with many feeling the burn of artificially-inflated prices for their prescription drugs. “Louisiana patients rely on generic drugs every day and they have felt the burn from the alleged conspiracy,” said General Landry. “I am proud to join General Tong in these efforts to ensure those who have harmed patients are brought to justice.”
The lawsuit seeks damages, civil penalties, and actions by the court to restore competition to the generic drug market. The outcome of the lawsuit could have significant implications for the pharmaceutical industry and for patients who rely on generic drugs. As the case moves forward, it is likely to be closely watched by those affected by the alleged price-fixing scheme.
In a statement, General Landry emphasized the importance of holding drug companies accountable for their actions. “We will not stand idly by while companies engage in deceptive practices that harm our citizens,” he said. “We will continue to fight for the rights of Louisiana patients and work to ensure that those responsible for this alleged conspiracy are held accountable.”
Related Federal Cases
- 23andMe Faces Legal Fire for Genetic Data Sale · Washington
- Live Nation Faces Trial Over Monopoly Practices · Washington
- 23andMe Faces Lawsuit for Selling Genetic Data · Washington
- Hernandez-Velazquez Gets 15+ Years for Brutal Sex Trafficking · Mississippi
- Amgen Pays $71M for Pushing Drugs Off-Label · Washington
Key Facts
- State: Louisiana
- Agency: Louisiana AG
- Category: Fraud & Financial Crimes
- Source: Official Source ↗
🔒 Get the grimiest stories delivered weekly. Subscribe free →
Browse More
MORE FEDERAL CRIME NEWS
US NewsUS NewsUS NewsUS News